After a very stagnant time in biotech M&A some deals emerging overnight.....
https://www.biopharmadive.com/news/johnson-johnson-ambrx-acquire-deal-antibody-drug-conjugate-prostate/703867/
In the cancer area, but at least some decent M&A activity. Those poor investment bankers are going hungry:
https://www.copyright link/wealth/investing/deal-making-languishes-at-decade-low-on-private-equity-drought-20230928-p5e8e1
(AFR)
PAR. SP, page-560
-
- There are more pages in this discussion • 475 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.95M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 23.5¢ | 22.0¢ | $65.40K | 290.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 96390 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 138166 | 5 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |